In fact agents targeting survivin are currently in phase I and phase II clinical trials in patients with advanced cancer where methods of inhibition include antisense oligonucleotides (ASOs), transcriptional repressors, and immunotherapy [10], [14], [22]. Here, BIRC5 is linked to cancer.